BL 8040

Drug Profile

BL 8040

Alternative Names: 4F-Benzoyl-TN14003; BKT-140; BL-8040; TN-14003

Latest Information Update: 20 Jan 2017

Price : $50

At a glance

  • Originator Kyoto University
  • Developer Biokine Therapeutics; BioLineRx; Merck AG; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Peptides
  • Mechanism of Action Apoptosis stimulants; Cell movement activators; CXCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Stem cell mobilisation
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Pancreatic cancer; Stem cell mobilisation
  • Phase I/II Aplastic anaemia; Multiple myeloma; Myelodysplastic syndromes
  • Preclinical Autoimmune disorders; Chronic myeloid leukaemia; Thrombocytopenia

Most Recent Events

  • 17 Jan 2017 BioLineRx initiates enrolment in second phase IIa trial for Pancreatic cancer (Combination therapy, Metastatic disease) in USA
  • 01 Dec 2016 BioLineRx initiates enrolment in a phase II trial for Pancreatic cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (NCT02907099)
  • 03 Nov 2016 Updated efficacy and adverse events data from a phase IIa trial in Acute myeloid leukaemia released by BioLineRx
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top